INTRODUCTIONVismodegib is a first-in-class FDA-approved oral drug for basal cell carcinomas (BCCs) deemed unsuitable for surgical resection or radiotherapy. Release of this drug was fast-tracked for January 2012 due to…
Read More
INTRODUCTION IncobotulinumtoxinA (INCO; Xeomin® in the United States, Canada / “botulinum toxin A free of complexing proteins» or Bocouture® in Europe and other parts of the world) is distributed by…
Read More
INTRODUCTIONActinic keratosis (AK) is one of the most common dermatologic diagnoses that affects individuals ≥40 years (11–50% of the population in the United States and Australia,1 and 11–25% in Europe2,3).…
Read More
INTRODUCTION Monoclonal antibodies (mAb) are a growing area in the therapeutic armamentarium of numerous conditions including various cancers, autoimmune diseases, psoriasis, transplant rejection and cardiovascular diseases among others1. They allow…
Read More
INTRODUCTIONLeuprolide acetate is a gonadotropin-releasing hormone agonist used in the treatment of hormone responsive cancers such as prostate cancer and breast cancer, in addition to gynecologic disorders like endometriosis or…
Read More
INTRODUCTION Rosacea fulminans (RF) is a rare and severe form of rosacea characterized by the sudden eruption of coalescing papules and pustules, and large cystic nodules limited almost exclusively to…
Read More
The Department of Dermatology at the University of Oklahoma Health Sciences Center came into existence in 1916 and is quickly approaching one century of providing healthcare to the citizens of…
Read More
DISCLOSURES The author has no relevant conflicts of interest to disclose.AUTHOR CORRESPONDENCEJulie Nguyen MDJulie-Nguyen@ouhsc.edu
Read More
CASE REPORTA 66-year-old African-American female presented with a two centimeter lichenified, scaly, and excoriated plaque on the left areola (Figure 1). The asymptomatic plaque had been present for less than…
Read More
Merck and MK-3475 for Advanced Melanoma Merck has announced that the FDA has accepted for review the Biologics License Application (BLA) for MK-3475, Merck’s investigational anti-PD-1 antibody, for the treatment…
Read More
Acne is perhaps the most prevalent skin disease in Western societies,1 yet our understanding of it still remains largely incomplete. We know that the primary pathogenic factors in acne vulgaris…
Read More
Re-evaluating Treatment Targets in Acne Vulgaris: Adapting to a New Understanding of Pathophysiology
INTRODUCTION Two primary factors are changing current approaches to the management of acne vulgaris (AV): the continuously evolving role of Propionibacterium acnes in the pathophysiology of AV and emerging evidence…
Read More
